霍奇金淋巴瘤治疗前18F-FDG PET影像组学特征的预后价值
结果显示灰度游程矩阵的强度不均匀性和Ann Arbor分期是PFS与OS的独立预测因子,SUV峰度是PFS的独立预测因子,基于3个风险预测因子构建的预后评分系统较当前分期系统进一步改善了风险分层。
要点
- 强度不均匀性和Ann Arbor分期是HL患者PFS与OS的独立预测因子。
- SUV峰度是PFS的独立预测因子。
- 基于3个风险预测因子的评分系统较Ann Arbor分期进一步改善风险分层。
核心结论
- 影像组学特征强度不均匀性是HL患者PFS和OS的独立预后预测因子。
- 基于强度不均匀性、Ann Arbor分期和SUV峰度构建的预后评分系统可能较当前Ann Arbor分期系统更有利于风险分层以指导治疗。
研究设计与样本
- 从PET图像中为每例患者提取450个影像组学特征。
- 采用ROC曲线、Cox比例风险回归和Kaplan-Meier分析评估临床与影像组学特征对PFS和OS的预后意义。
主要发现
- 灰度游程矩阵提取的强度不均匀性与PFS独立相关(HR=22.8,P<0.001),与OS独立相关(HR=14.5,P=0.012)。
- Ann Arbor分期与PFS独立相关(HR=7.6,P=0.024),与OS独立相关(HR=8.5,P=0.048)。
- SUV峰度是PFS的独立预后因素(HR=6.6,P=0.026)。
- 基于3个风险预测因子构建的预后评分系统较当前分期分类进一步改善风险分层(P<0.001)。
关键数值与推荐
- 强度不均匀性预测PFS的HR=22.8(P<0.001),预测OS的HR=14.5(P=0.012)。
- Ann Arbor分期预测PFS的HR=7.6(P=0.024),预测OS的HR=8.5(P=0.048)。
- SUV峰度预测PFS的HR=6.6(P=0.026)。
- 预后评分系统改善风险分层的P<0.001。
临床怎么用
- 治疗前18F-FDG PET影像组学分析可用于HL患者的预后风险评估。
- 强度不均匀性、Ann Arbor分期和SUV峰度可共同用于构建预后评分系统以辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study investigated whether a radiomic analysis of pretreatment F-FDG PET can predict prognosis in patients with Hodgkin lymphoma (HL). METHODS: Forty-two patients who were diagnosed as having HL and underwent pretreatment F-FDG PET scans were retrospectively enrolled. For each patient, we extracted 450 radiomic features from PET images. The prognostic significance of the clinical and radiomic features was assessed in relation to progression-free survival (PFS) and overall survival (OS). Receiver operating characteristic curve, Cox proportional hazards regression, and Kaplan-Meier analyses were performed to examine the potential independent predictors and to evaluate the predictive value. RESULTS: Intensity nonuniformity extracted from a gray-level run-length matrix and the Ann Arbor stage were independently associated with PFS (hazard ratio [HR] = 22.8, P < 0.001; HR = 7.6, P = 0.024) and OS (HR = 14.5, P = 0.012; HR = 8.5, P = 0.048), respectively. In addition, SUV kurtosis was an independent prognosticator for PFS (HR = 6.6, P = 0.026). We devised a prognostic scoring system based on these 3 risk predictors. The proposed scoring system further improved the risk stratification of the current staging classification (P < 0.001). CONCLUSIONS: The radiomic feature intensity nonuniformity is an independent prognostic predictor of PFS and OS in patients with HL. We devised a prognostic scoring system, which may be more beneficial for patient risk stratification in guiding therapy compared with the current Ann Arbor staging system.
引用
- Lue KH, Wu YF, Liu SH, et al. Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma. Clin Nucl Med. 2019. PMID: 31306204. doi:10.1097/RLU.0000000000002732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。